NFE2L2 and gastric cancer: In GC, the expression of NFE2L2 has been linked to several aggressive cancer characteristics, such as larger tumor size, increased tumor depth, lymph node metastasis, lymphovascular invasion, higher tumor stage, and poorer survival, and is also linked to resistance to 5‐FU–based chemotherapy [52].